The owners of Trilliant Holdings Inc. are exploring a sale of the smart-grid technology company after attracting inquiries from potential buyers, according to people familiar with the matter. Founder Steve Muzzo owns a majority stake in the business alongside Toronto-based private credit firm Third Eye Capital . After receiving expressions of interest, they hired Jefferies Financial Group Inc. to ...
The owners of Trilliant Holdings Inc. are exploring a sale of the smart-grid technology company after attracting inquiries from potential buyers, according to people familiar with the matter. Founder Steve Muzzo owns a majority stake in the business alongside Toronto-based private credit firm Third Eye Capital . After receiving expressions of interest, they hired Jefferies Financial Group Inc. to speak with potential bidders, the people said, asking not to be identified discussing private deliberations. The talks are at an early stage and there’s no certainty they’ll result in a deal, according to the people. “Trilliant continues to perform strongly, we had a record year in 2025, and are on track for another record year across our global business in 2026,” Trilliant Executive Chairman Andrew White said in an email. “As is common for companies operating in sectors experiencing significant infrastructure investment and consolidation like ours, shareholders periodically review inbound strategic interest with the assistance of advisers.” Muzzo and Third Eye Capital didn’t reply to requests for comment. Trilliant sells technology to electrical utilities, helping them monitor usage, manage outages and integrate renewable energy into the grid. It also offers hardware and software solutions for water utilities. Third Eye is a Toronto-based alternative credit manager that provides financing to middle-market companies through private loans. Firms such as Third Eye often combine debt and equity investments, allowing them to fund businesses while earning returns through multiple parts of the capital structure. The original loan from Third Eye was structured as a payment-in-kind facility, according to the people. So-called PIK loans allow the borrower to add to the principal of the loan instead of paying cash interest — meaning the balance grows quickly. Stronger cash generation has allowed Trilliant to reduce the debt, the people said. Trilliant expects to secure new bookings f...
Ten players from Jamaican side Mount Pleasant have been denied a visa to enter the United States for Wednesday's Concacaf Champions Cup tie against LA Galaxy. Mount Pleasant, winners of the 2025 Concacaf Caribbean Cup, are set to make their Champions Cup debut against Galaxy at the Dignity Health Sports Park in California. The Jamaican side have been forced to call up a number of academy players f...
Ten players from Jamaican side Mount Pleasant have been denied a visa to enter the United States for Wednesday's Concacaf Champions Cup tie against LA Galaxy. Mount Pleasant, winners of the 2025 Concacaf Caribbean Cup, are set to make their Champions Cup debut against Galaxy at the Dignity Health Sports Park in California. The Jamaican side have been forced to call up a number of academy players for the fixture. "We don't want to just show up for the game, we want to be able to compete, but we are not being given the opportunity to be at our best," Mount Pleasant sporting director Paul Christie told the Jamaica Observer., external Mount Pleasant's squad includes seven players from the Caribbean island nation of Haiti. United States President Donald Trump announced a partial travel ban on nationals from Haiti in June 2025. Exemptions are in place for events such as the World Cup, which is being co-hosted by the US this summer. The Champions Cup is organised by Concacaf and involves teams from North America, Central America and the Caribbean. It is unclear if an exemption is in place for the tournament. BBC Sport has contacted Concacaf and Mount Pleasant for comment.
PC, Xbox, Nintendo Switch, PlayStation 4/5; Tribute Games Inc A treat for nostalgia fans and completists, but there’s little new in this rehashing of a classic that feels like an add-on rather than a fully fledged adventure It’s 20XX, and unrepentant slacker Scott Pilgrim and his friends are revelling in the throes of young adulthood. They’re skint, but in a cool way that’s unrecognisable today (n...
PC, Xbox, Nintendo Switch, PlayStation 4/5; Tribute Games Inc A treat for nostalgia fans and completists, but there’s little new in this rehashing of a classic that feels like an add-on rather than a fully fledged adventure It’s 20XX, and unrepentant slacker Scott Pilgrim and his friends are revelling in the throes of young adulthood. They’re skint, but in a cool way that’s unrecognisable today (not least because nobody can afford to live near downtown Toronto). For many readers, the Scott Pilgrim graphic novels were a cultural touchpoint, a story about emotional immaturity, growing as a person and ultimately defeating youthful arrogance. Having cemented itself as a cult classic with an Edgar Wright movie , a 2010 tie-in game and a Netflix miniseries, it’s now back in the form of a raucous action-adventure game, Scott Pilgrim EX. This is a homecoming of sorts for developer Tribute Games, which was formed by ex-Ubisoft employees who worked on the 2010 Scott Pilgrim game. Having established themselves as beat ’em up revivalists with Teenage Mutant Ninja Turtles: Shredder’s Revenge and Marvel Cosmic Invasion, the team has stepped up for another crack at this essential coming-of-age tale. Scott Pilgrim EX feels like a passion project, so they have the Powers of Love and Understanding on their side. Continue reading...
In recent trading, shares of Tronox Holdings PLC (Symbol: TROX) have crossed above the average analyst 12-month target price of $15.14, changing hands for $15.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental busine...
In recent trading, shares of Tronox Holdings PLC (Symbol: TROX) have crossed above the average analyst 12-month target price of $15.14, changing hands for $15.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 7 different analyst targets within the Zacks coverage universe contributing to that average for Tronox Holdings PLC, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $11.00. And then on the other side of the spectrum one analyst has a target as high as $18.00. The standard deviation is $2.34. But the whole reason to look at the average TROX price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with TROX crossing above that average target price of $15.14/share, investors in TROX have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $15.14 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Tronox Holdings PLC: Recent TROX Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 4 4 4 3 Buy ratings: 0 0 0 0 Hold ratings: 3 3 3 4 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.86 1.86 1.86 2.14 The average rating presented in ...
Maximusnd/iStock via Getty Images The ongoing conflict involving Iran and the disruption to energy markets has moved beyond headline risk and is now influencing expectations for growth, inflation and policy. As of March 9, oil prices briefly breached the $100 per barrel threshold — a development that shifts the macro conversation compared to last week . What happened in the first week of the confl...
Maximusnd/iStock via Getty Images The ongoing conflict involving Iran and the disruption to energy markets has moved beyond headline risk and is now influencing expectations for growth, inflation and policy. As of March 9, oil prices briefly breached the $100 per barrel threshold — a development that shifts the macro conversation compared to last week . What happened in the first week of the conflict? During the first week, energy markets absorbed the most visible impact. Crude oil briefly rose above $100 per barrel amid continued uncertainty surrounding flows through the Strait of Hormuz — a critical corridor for global crude and liquid natural gas (LNG) shipments. Leadership dynamics inside Iran have also evolved. The country’s newly announced leader, Mojtaba Khamenei, is widely viewed as a hard-liner and seen as potentially extending the conflict, suggesting the risk of a protracted disruption to energy supplies has increased. Our measure of investor sentiment moved from overbought to directionally slightly pessimistic last Friday for the first time since November. Even so, current conditions do not reflect panic or forced repositioning. Overnight selling pressure eased somewhat following reports that Saudi Arabia may offer additional crude supply via the Red Sea, though uncertainty around energy flows remains elevated. How is this impacting markets going forward? Sustained oil prices above $100 would shift the impact from a volatility event to a growth consideration. At current levels, the drag on U.S. growth is estimated at approximately 0.5 percentage points. The impact is likely more pronounced outside the United States — particularly in Asia — where roughly 80–90% of crude and LNG transiting the Strait of Hormuz flows. In that context, growth risks have moved up from low to medium . Elevated energy prices also introduce renewed upside risks to inflation. That dynamic limits central bank flexibility. The Federal Reserve (Fed) is unlikely to come in proactivel...
Record Childhood Obesity Surge Puts MAHA Health Goals In Focus Childhood obesity in the United States has reached its highest recorded level, renewing debate over school meals, physical activity, nutrition policy and the role of weight-loss medications for young people, according to The Hill . Data from the Centers for Disease Control and Prevention shows more than 1 in 5 children and teenagers we...
Record Childhood Obesity Surge Puts MAHA Health Goals In Focus Childhood obesity in the United States has reached its highest recorded level, renewing debate over school meals, physical activity, nutrition policy and the role of weight-loss medications for young people, according to The Hill . Data from the Centers for Disease Control and Prevention shows more than 1 in 5 children and teenagers were obese between 2021 and 2023, up from 5.2 percent in the early 1970s. About 7 percent now meet the criteria for severe obesity. The issue has become part of the “Make America Healthy Again” initiative connected to Robert F. Kennedy Jr. at the U.S. Department of Health and Human Services. Discussions around solutions often center on improving school meals and increasing opportunities for physical activity. Nutrition advocates say school meal programs play a critical role in children’s diets. For some students, breakfast and lunch at school are the most nutritious meals they receive each day. Erin Hysom of the Food Research & Action Center said pandemic school closures disrupted that support. “They’re noting that this increase in obesity occurred during COVID-19 and that jump in childhood obesity happened during the years when millions of kids lost access to reliable school meals,” she said. The Hill writes that only nine states currently provide universal free breakfast and lunch to public school students, though others are considering similar programs. Federal officials have also promoted updated nutrition guidance that emphasizes whole foods and discourages ultra-processed products, which account for more than 60 percent of children’s daily calories. Researchers say improving school meals will require additional funding, trained staff and better kitchen equipment so schools can prepare more fresh food. At the same time, the administration has approved requests from 18 states to remove soda and junk food from certain food assistance programs and announced new nutrition tr...
In recent trading, shares of J.B. Hunt Transport Services, Inc. (Symbol: JBHT) have crossed above the average analyst 12-month target price of $149.52, changing hands for $151.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the f...
In recent trading, shares of J.B. Hunt Transport Services, Inc. (Symbol: JBHT) have crossed above the average analyst 12-month target price of $149.52, changing hands for $151.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 23 different analyst targets within the Zacks coverage universe contributing to that average for J.B. Hunt Transport Services, Inc., but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $103.00. And then on the other side of the spectrum one analyst has a target as high as $172.00. The standard deviation is $15.879. But the whole reason to look at the average JBHT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with JBHT crossing above that average target price of $149.52/share, investors in JBHT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $149.52 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover J.B. Hunt Transport Services, Inc.: Recent JBHT Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 11 12 12 13 Buy ratings: 1 1 1 1 Hold ratings: 10 9 9 9 Sell ratings: 1 1 1 1 Strong sell ratings: 0 0 0 0 Average r...
In recent trading, shares of Nexa Resources SA (Symbol: NEXA) have crossed above the average analyst 12-month target price of $9.70, changing hands for $9.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business d...
In recent trading, shares of Nexa Resources SA (Symbol: NEXA) have crossed above the average analyst 12-month target price of $9.70, changing hands for $9.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 4 different analyst targets within the Zacks coverage universe contributing to that average for Nexa Resources SA, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $8.50. And then on the other side of the spectrum one analyst has a target as high as $10.50. The standard deviation is $0.852. But the whole reason to look at the average NEXA price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with NEXA crossing above that average target price of $9.70/share, investors in NEXA have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $9.70 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Nexa Resources SA: Recent NEXA Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 0 0 0 0 Buy ratings: 0 0 0 0 Hold ratings: 3 3 3 3 Sell ratings: 1 1 1 0 Strong sell ratings: 0 0 0 0 Average rating: 3.25 3.25 3.25 3.0 The average rating presented in the last ro...
In recent trading, shares of Banco Bradesco SA (Symbol: BBD) have crossed above the average analyst 12-month target price of $2.98, changing hands for $3.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business de...
In recent trading, shares of Banco Bradesco SA (Symbol: BBD) have crossed above the average analyst 12-month target price of $2.98, changing hands for $3.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 5 different analyst targets within the Zacks coverage universe contributing to that average for Banco Bradesco SA, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $2.00. And then on the other side of the spectrum one analyst has a target as high as $4.10. The standard deviation is $0.749. But the whole reason to look at the average BBD price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BBD crossing above that average target price of $2.98/share, investors in BBD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $2.98 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Banco Bradesco SA: Recent BBD Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 2 1 0 0 Buy ratings: 0 0 0 0 Hold ratings: 3 4 5 5 Sell ratings: 0 0 0 0 Strong sell ratings: 1 1 1 1 Average rating: 2.58 2.92 3.25 3.25 The average rating presented in the last row of ...
In recent trading, shares of Methanex Corp (Symbol: MEOH) have crossed above the average analyst 12-month target price of $51.90, changing hands for $53.01/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business dev...
In recent trading, shares of Methanex Corp (Symbol: MEOH) have crossed above the average analyst 12-month target price of $51.90, changing hands for $53.01/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 10 different analyst targets within the Zacks coverage universe contributing to that average for Methanex Corp, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $38.00. And then on the other side of the spectrum one analyst has a target as high as $65.00. The standard deviation is $8.319. But the whole reason to look at the average MEOH price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with MEOH crossing above that average target price of $51.90/share, investors in MEOH have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $51.90 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Methanex Corp: Recent MEOH Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 6 7 7 8 Buy ratings: 1 1 2 2 Hold ratings: 3 2 1 0 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 1 Average rating: 1.7 1.5 1.4 1.55 The average rating presented in the last row of the...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR SSGA US Sector Rotation ETF (Symbol: XLSR), we found that the implied analyst target price for the ETF bas...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR SSGA US Sector Rotation ETF (Symbol: XLSR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $67.85 per unit. With XLSR trading at a recent price near $60.52 per unit, that means that analysts see 12.11% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XLSR's underlying holdings with notable upside to their analyst target prices are Walt Disney Co. (Symbol: DIS), Alphabet Inc (Symbol: GOOG), and Apple Inc (Symbol: AAPL). Although DIS has traded at a recent price of $101.66/share, the average analyst target is 31.52% higher at $133.70/share. Similarly, GOOG has 23.89% upside from the recent share price of $306.01 if the average analyst target price of $379.11/share is reached, and analysts on average are expecting AAPL to reach a target price of $295.90/share, which is 13.86% above the recent price of $259.87. Below is a twelve month price history chart comparing the stock performance of DIS, GOOG, and AAPL: Combined, DIS, GOOG, and AAPL represent 8.65% of the SPDR SSGA US Sector Rotation ETF. Below is a summary table of the current analyst target prices discussed above: Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target SPDR SSGA US Sector Rotation ETF XLSR $60.52 $67.85 12.11% Walt Disney Co. DIS $101.66 $133.70 31.52% Alphabet Inc GOOG $306.01 $379.11 23.89% Apple Inc AAPL $259.87 $295.90 13.86% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A hig...
In recent trading, shares of RPC, Inc. (Symbol: RES) have crossed above the average analyst 12-month target price of $8.17, changing hands for $8.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developmen...
In recent trading, shares of RPC, Inc. (Symbol: RES) have crossed above the average analyst 12-month target price of $8.17, changing hands for $8.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 3 different analyst targets within the Zacks coverage universe contributing to that average for RPC, Inc., but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $7.50. And then on the other side of the spectrum one analyst has a target as high as $9.00. The standard deviation is $0.763. But the whole reason to look at the average RES price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with RES crossing above that average target price of $8.17/share, investors in RES have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $8.17 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover RPC, Inc.: Recent RES Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 0 0 0 0 Buy ratings: 0 0 0 0 Hold ratings: 2 2 2 2 Sell ratings: 0 0 0 0 Strong sell ratings: 1 1 1 1 Average rating: 3.67 3.67 3.67 3.67 The average rating presented in the last row of the above table above is...
In recent trading, shares of Xenon Pharmaceuticals Inc (Symbol: XENE) have crossed above the average analyst 12-month target price of $56.39, changing hands for $62.67/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental ...
In recent trading, shares of Xenon Pharmaceuticals Inc (Symbol: XENE) have crossed above the average analyst 12-month target price of $56.39, changing hands for $62.67/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 19 different analyst targets within the Zacks coverage universe contributing to that average for Xenon Pharmaceuticals Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $47.00. And then on the other side of the spectrum one analyst has a target as high as $66.00. The standard deviation is $5.468. But the whole reason to look at the average XENE price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with XENE crossing above that average target price of $56.39/share, investors in XENE have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $56.39 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Xenon Pharmaceuticals Inc: Recent XENE Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 19 18 18 18 Buy ratings: 2 2 2 2 Hold ratings: 1 1 1 1 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 1.18 1.19 1.19 1.19 The aver...
In recent trading, shares of Tidewater Inc (Symbol: TDW) have crossed above the average analyst 12-month target price of $78.33, changing hands for $81.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business deve...
In recent trading, shares of Tidewater Inc (Symbol: TDW) have crossed above the average analyst 12-month target price of $78.33, changing hands for $81.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 6 different analyst targets within the Zacks coverage universe contributing to that average for Tidewater Inc , but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $55.00. And then on the other side of the spectrum one analyst has a target as high as $117.00. The standard deviation is $22.992. But the whole reason to look at the average TDW price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with TDW crossing above that average target price of $78.33/share, investors in TDW have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $78.33 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Tidewater Inc : Recent TDW Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 1 1 1 1 Buy ratings: 2 2 2 2 Hold ratings: 5 5 4 4 Sell ratings: 0 0 0 0 Strong sell ratings: 1 1 2 2 Average rating: 2.78 2.78 3.0 3.0 The average rating presented in the last row of the ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Long/Short Equity ETF (Symbol: FTLS), we found that the implied analyst target price for the ETF ba...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Long/Short Equity ETF (Symbol: FTLS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $82.80 per unit. With FTLS trading at a recent price near $70.85 per unit, that means that analysts see 16.87% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FTLS's underlying holdings with notable upside to their analyst target prices are American Superconductor Corp. (Symbol: AMSC), StepStone Group Inc (Symbol: STEP), and Roblox Corp (Symbol: RBLX). Although AMSC has traded at a recent price of $28.99/share, the average analyst target is 80.23% higher at $52.25/share. Similarly, STEP has 76.16% upside from the recent share price of $45.25 if the average analyst target price of $79.71/share is reached, and analysts on average are expecting RBLX to reach a target price of $106.82/share, which is 70.50% above the recent price of $62.65. Below is a twelve month price history chart comparing the stock performance of AMSC, STEP, and RBLX: Below is a summary table of the current analyst target prices discussed above: Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target First Trust Long/Short Equity ETF FTLS $70.85 $82.80 16.87% American Superconductor Corp. AMSC $28.99 $52.25 80.23% StepStone Group Inc STEP $45.25 $79.71 76.16% Roblox Corp RBLX $62.65 $106.82 70.50% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading ...
The pipeline of drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicting the annual number of deaths linked to drug-resistant infections globally will double to 8 million by 2050. The number of projects from large pharma companies has shrunk by 35% over the past five years, from 92 to 60 medicines in development, according to ...
The pipeline of drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicting the annual number of deaths linked to drug-resistant infections globally will double to 8 million by 2050. The number of projects from large pharma companies has shrunk by 35% over the past five years, from 92 to 60 medicines in development, according to a report from the Access to Medicine Foundation (AMF), a Netherlands-based non-profit group, and the Wellcome Trust. “Overall, however, the R&D pipeline remains worryingly thin, and industry investment has lost momentum,” said Jayasree K Iyer, the chief executive of AMF. She described drug resistance as the biggest single threat to healthcare worldwide. More than 1 million people die each year directly from drug resistant infections but they contribute to 4 million deaths worldwide a year. Both figures are forecast to double by 2050 – to nearly 2 million and more than 8 million respectively. The UK’s GSK is leading the way in antimicrobial resistance research and development (R&D) with 30 projects and is one of just three big pharma companies that continue to invest in this area, the report found. The other two big players are Japan’s Shionogi and Otsuka, while the US drugmaker Pfizer, which was joint first with GSK in 2021, has fallen back. Britain’s biggest pharmaceutical company, AstraZeneca, is not included in the ranking because it does not have an antibiotic portfolio, as infectious diseases has never been its focus. The report assesses the efforts of 25 companies, including seven large research-based firms, 10 generic medicine manufacturers and eight smaller drug developers, or biotechs. Iyer said three recently approved antibiotics and seven other promising medicines in late-stage development showed “it is possible to tilt the battle against superbugs in humanity’s favour”. In December, the US health regulator approved the Californian biotech Innoviva’s zoliflodacin...
格隆汇3月10日｜雷诺集团首席技术官、ACDC总经理 Philippe Brunet 今日表示，雷诺集团虽然在中国市场未销售整车，但未来将持续在中国的业务，主要包括：继续在中国开发新车型，包括和吉利共享的平台，也会为海外市场进行车型开发；对欧洲市场进行零部件采购；在智能化方面借助中国企业的能力，使雷诺成为重要的市场参与者。
格隆汇3月10日｜雷诺集团首席技术官、ACDC总经理 Philippe Brunet 今日表示，雷诺集团虽然在中国市场未销售整车，但未来将持续在中国的业务，主要包括：继续在中国开发新车型，包括和吉利共享的平台，也会为海外市场进行车型开发；对欧洲市场进行零部件采购；在智能化方面借助中国企业的能力，使雷诺成为重要的市场参与者。
In recent trading, shares of BanColombia SA (Symbol: CIB) have crossed above the average analyst 12-month target price of $42.00, changing hands for $42.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business dev...
In recent trading, shares of BanColombia SA (Symbol: CIB) have crossed above the average analyst 12-month target price of $42.00, changing hands for $42.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 3 different analyst targets within the Zacks coverage universe contributing to that average for BanColombia SA, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $41.00. And then on the other side of the spectrum one analyst has a target as high as $44.00. The standard deviation is $1.732. But the whole reason to look at the average CIB price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with CIB crossing above that average target price of $42.00/share, investors in CIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $42.00 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover BanColombia SA: Recent CIB Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 2 2 1 1 Buy ratings: 0 0 0 0 Hold ratings: 0 1 1 1 Sell ratings: 0 0 1 1 Strong sell ratings: 0 0 0 0 Average rating: 1.0 1.67 2.67 2.67 The average rating presented in the last row of the ...
The Ministry of Justice has previously said Huntley's crime "remains one of the most shocking and devastating cases in our nation's history, and our thoughts are with their families".
The Ministry of Justice has previously said Huntley's crime "remains one of the most shocking and devastating cases in our nation's history, and our thoughts are with their families".
hapabapa NIO ( NIO ) delivered strong top-line growth in Q4, with total revenue reaching roughly RMB87.5B for the quarter, supported by higher deliveries and a richer mix of newer models. Vehicle sales were up 65% quarter-over-quarter and were 81% higher than a year ago. Gross profit improved to about RMB11.9B, and gross margin expanded meaningfully versus the prior year, reflecting better vehicle...
hapabapa NIO ( NIO ) delivered strong top-line growth in Q4, with total revenue reaching roughly RMB87.5B for the quarter, supported by higher deliveries and a richer mix of newer models. Vehicle sales were up 65% quarter-over-quarter and were 81% higher than a year ago. Gross profit improved to about RMB11.9B, and gross margin expanded meaningfully versus the prior year, reflecting better vehicle margins and cost-down initiatives. Notably, the Chinese electric vehicle maker company swung to an operating profit for the first time, with non-GAAP of RMB1.25B. Management highlighted that these Q4 results marked an inflection point from the heavy losses seen in Q4 2024, driven by volume leverage, product mix, and tighter operating expense control. The company delivered 27,182 vehicles and 20,797 vehicles in January and February, respectively. As of February 28, the company had delivered 47,979 vehicles in 2026, with cumulative deliveries reaching 1,045,571. "In 2026, we will continue to enhance operational efficiency and optimize cost and deliver stronger, more sustainable performance for our users, partners, and shareholders," stated NIO ( NIO ) CFO Stanley Yu Qu. Nio ( NIO ) expected total deliveries in Q1 to be in the 80K and 83K unit range, representing a year-over-year increase of 90.1% to 97.2%. Shares of NIO ( NIO ) rallied 5.3% in premarket trading on Tuesday. XPeng ( XPEV ) tracked 0.8% higher, while Li Auto ( LI ) was off 0.4%. More on NIO NIO Q4 Preview: From Breakeven Doubts To Pre-Profit, The Margin Expansion Story Begins NIO: Risks Behind Q4 2025's Breakeven Guidance NIO: The Patient Wait For Consistent Profits NIO misses Q4 EPS street views NIO eyes first operating profit in Q4 on strong sales growth
Oracle (ORCL) Shares in Oracle were the number one trending ticker on Yahoo Finance on Tuesday morning as the AI infrastructure company is set to report third quarter earnings after the bell. Wall Street analysts expect adjusted earnings per share of $1.70, up from $1.47 a year earlier. Revenue is forecast to rise 20% to $16.9bn. Oracle’s cloud segment is expected to generate $8.8bn in revenue, wh...
Oracle (ORCL) Shares in Oracle were the number one trending ticker on Yahoo Finance on Tuesday morning as the AI infrastructure company is set to report third quarter earnings after the bell. Wall Street analysts expect adjusted earnings per share of $1.70, up from $1.47 a year earlier. Revenue is forecast to rise 20% to $16.9bn. Oracle’s cloud segment is expected to generate $8.8bn in revenue, while its software segment is projected to bring in $5.9bn. Remaining performance obligations, which represent signed contracts yet to be fulfilled, are estimated to exceed $470.7bn, sharply higher than the $130bn recorded in the same quarter of 2025. Read more: FTSE 100 LIVE: Stocks surge after Trump says Iran war could end 'very soon' The results are expected to offer a gauge of demand for artificial intelligence infrastructure deals, as Oracle sits on a large backlog of AI-related contracts alongside rising debt and negative free cash flow. Hewlett Packard Enterprise (HPE) Shares in Hewlett Packard Enterprise (HPE) rose almost 3% in pre-market trading after the company raised its earnings outlook while moving to secure memory supplies amid a shortage. HPE increased its forecast for adjusted earnings per share by five cents to a range of $2.30 to $2.50. The company reaffirmed its overall revenue growth outlook for 2026 and raised its forecast for networking revenue growth to between 68% and 73%. The server and networking group said on Monday that strong demand from artificial intelligence and data centre developers was continuing to support sales of its networking products. HPE has also taken several steps to secure sufficient memory as tight supply conditions drive prices higher. Read more: Oil drops as Trump says US looking to keep prices down amid Iran war Net profit was $423m, or 31 cents a share, in the quarter ended 31 January, compared with $598m, or 44 cents a share, a year earlier. Excluding certain items, adjusted earnings were 65 cents a share, ahead of the 59 ce...
Jimmy Energy SAS , a French nuclear startup backed by billionaire Pierre-Edouard Sterin , raised €80 million ($92 million) to complete the design of its small modular reactor and start construction by 2029. The French government is providing half of the funding, while Credit Mutuel Alliance Federale is leading private sector financing, Paris-based Jimmy Energy said in a statement Tuesday. Some exi...
Jimmy Energy SAS , a French nuclear startup backed by billionaire Pierre-Edouard Sterin , raised €80 million ($92 million) to complete the design of its small modular reactor and start construction by 2029. The French government is providing half of the funding, while Credit Mutuel Alliance Federale is leading private sector financing, Paris-based Jimmy Energy said in a statement Tuesday. Some existing shareholders, including Sterin’s investment firm Otium Capital and Paris Mouratoglou’s Eren Groupe , also participated in the new funding round. Jimmy Energy is among the companies seeking to commercialize the next wave of nuclear technology by designing so-called SMRs to meet an expected increase in demand for carbon-free energy. The US, Europe and China are racing to develop such plants that would be cheaper and faster to build than traditional large-scale reactors. “The goal is to complete the detailed design with suppliers, and to obtain the approval from the nuclear safety authority for the first of a kind,” Antoine Guyot, co-founder and chief executive officer of the six-year-old French startup, said in an interview. The new money will also help Jimmy Energy, which employs 80 people, beef up its engineering capacity. The firm previously raised more than €50 million. The startup is targeting its reactors at European food, paper and chemicals makers, generating high-temperature heat for processes that would be more competitive than using natural gas, Guyot said. The 60-megawatt units would take two-and-a-half years to build, and cost between €100 million and €200 million. The company plans to start construction in 2029 of the first reactor, which would supply steam for a sugar and alcohol producer east of Paris, the CEO said. Jimmy’s gas-cooled reactors will use longer-burning TRISO fuel, which will initially be supplied by Urenco Ltd. ’s plant in New Mexico. Read More: Advanced Nuclear Fuel Market Emerging as US Sets First Delivery